Whitepaper: Continuous wet granulation and fluid-bed drying
Continuous wet granulation and drying have long been a hot topic in pharmaceutical manufacturing. The QbCon® 1 system solves all existing problems.
List view / Grid view
Continuous wet granulation and drying have long been a hot topic in pharmaceutical manufacturing. The QbCon® 1 system solves all existing problems.
This paper takes a closer look at plastic storage bags for bioprocesses focusing on a shift from multilayer to single-layer storage solutions.
Glenn Abood, founder and CEO of rfxcel, explains how real-time environmental monitoring can combat supply chain shortcomings, providing companies with level of data integrity, traceability, transparency and security that is virtually beyond reproach.
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
With the appropriate formulation strategies, the challenges around poorly soluble compounds can indeed be overcome. Reducing development time and ultimately speeding up the route to market.
Disinfectants must be qualified on the surfaces in a pharmacopeial manufacturing environment prior to use in the facility. Building a study with robust parameters and avoiding common pitfalls is critical to avoid negative responses from regulatory agencies.
The LLT-BMT1 drug releasing contact lens was safe, well tolerated and may have reduced the incidence of hyperaemia in an early glaucoma trial.
The spin-out from the Universities of Helsinki and Eastern Finland will leverage years of research to test and bring to market a nasal spray vaccine against COVID-19.
What is dissolution testing, why is it critical, what to consider for your method validation? Learn more in this quick guide.
The novel microneedle array uses electroosmotic flow and a series of interconnected micropores to deliver large molecules or extract of fluid samples.
Key requirements to ensure patient safety in the present-day development and production of viral vaccines, and the challenges going forward.
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
iCON has improved delivery capacity by standardising the infrastructure for a flexible and readily available drug manufacturing facility.
iCON has improved delivery capacity by standardising the infrastructure for a flexible and readily available drug manufacturing facility.
This on-demand webinar will provide aspects of a sterility assurance program for a pharmaceutical product. Sterility assurance begins at the early stages of product development and follows through the entire product lifecycle.